key: cord-0763136-s3q7haha
authors: Janiak, Elizabeth; Belizaire, Carmela; Liu, Jessie; Fulcher, Isabel R
title: The Association of State-level Abortion Restrictions with Medication Abortion Service Delivery Innovations during the Early COVID-19 Pandemic
date: 2022-04-14
journal: Contraception
DOI: 10.1016/j.contraception.2022.04.003
sha: ae2758227f81ad8b1aa6e3a9bd8bbbcf5c83dbb4
doc_id: 763136
cord_uid: s3q7haha

OBJECTIVES: To assess whether state-level abortion restrictions resulted in differential uptake of innovative medication abortion practices such as changing ultrasound requirements, offering telehealth, or dispensing medications without a physical exam during the early COVID-19 pandemic. METHODS: We used data from a prospective national survey of abortion providers to assess the association between a novel index of state-level abortion hostility and adoption of medication abortion services innovations during the pandemic. RESULTS: Clinics in states with low or medium hostility were more likely to adopt innovative practices than those in high or extreme hostility states. CONCLUSIONS: Clinics in abortion hostile states were less likely to adopt clinical recommendations and public health best practices for abortion care during the COVID-19 pandemic.

During the COVID-19 pandemic, multiple health care services rapidly adapted to telehealth care delivery to sustain access while minimizing viral transmission risk. Among reproductive health services, medication abortion was a prime candidate for remote care as the medications used (mifepristone and misoprostol) are shelf-stable and easily self-administered [1] . Prior to the COVID-19 pandemic, the safety of medication abortion following a remote consultation was well established. Nonetheless, the distribution of the drug mifepristone remained highly restricted at the federal level by a Risk Evaluation and Mitigation Strategy (REMS) imposed by the US Food and Drug Administration (FDA) that requires in-person dispensing of the drug by or under the direction of a clinician, contrary to medical consensus [2] .

At the onset of the COVID-19 pandemic, leading clinical authorities in family planning developed guidance to encourage expansion of no-and low-test abortion care, including remote consultations followed by in-person drug dispensing without an exam, and telehealth abortion in which drugs are mailed directly to the patient [3] . In response to a lawsuit filed by clinicians seeking to deliver care remotely during the public health emergency, the federal in-person dispensing requirement for mifepristone was temporarily lifted [4] .

The promulgation of new clinical guidelines and relaxed federal regulations could have reduced close interpersonal contacts in the abortion clinical care setting on a national scale, thereby reducing associated viral transmission risk [5] . However, due to widespread state-level restrictions on abortion care, medication abortion service delivery innovations may not have become equally available in all states. We set out to assess whether state-level abortion restrictions were associated with lower likelihood of abortion care providers offering innovative service delivery options during the early COVID-19 pandemic.

We created an index of state-level abortion hostility and tested its association with adopting innovative medication abortion practice changes in response to the COVID-19 pandemic among clinics in a longitudinal nationwide survey of abortion providers. The index was created using published reports of state-level abortion policies as of October 1, 2020. To reduce keystroke error, two study team members independently transcribed restrictions from a centralized resource created by a research group and an advocacy group [6] . We then further validated the restrictions as listed by comparing the original source to two additional sources from not-for-profit research organizations [7, 8] . The study PI (EJ) adjudicated any discrepancies.

We additionally planned to leverage professional connections with legislative advocacy experts to further clarify which dates specific statutes were enacted or enjoined if necessary, but no such consultations were needed.

We tallied 13 specific state-level abortion restrictions for each US state and assigned each restriction a value of 1 for those with weak evidence of impact on abortion access outcomes or 2 for those with strong evidence of impact (Table 1; Figure 1 ). We then ranked states into quartiles, categorizing each state as having low (0-4 points), medium (5-12), high (13-17), or extreme (18-20) abortion restrictions (Supplemental Table 1 ). To separately estimate the association of global abortion hostility from the effect of laws that specifically prohibit care innovations such as no-exam visits and telemedicine, we created a separate binary variable to indicate if state-level restrictions specifically mandated a visit for medication abortion care by requiring either (1) an ultrasound or (2) in-person dispensing of mifepristone as a state law, in addition to the FDA requirement. Other studies of population-level health outcomes have used similar indices of abortion restrictions as the exposure of interest for their analyses [9, 10] .

Outcome data were obtained from online surveys conducted with a convenience sample of 72 members of the Society of Family Planning's nationwide Abortion Clinical Research Network at three time points during the early COVID-19 pandemic [11] . Surveys were completed by representatives of Network clinics, including some with more than one clinical location; in cases where clinical organizations spanned multiple states, respondents were instructed to report on their highest volume clinical site and to note the state in which that site was located. We included clinical sites that provide medication abortion services and responded to the third survey wave (November 2020) for a total sample size of 57. To prevent identification of any clinics in this small dataset, the deidentified dataset shared with our team by the Society excluded state names. We provided the Society with the classification of each US state according to our index, and they informed our team of the score of the state in which each site was located.

Thus, the final dataset excluded state name but included classification of each site according to our state hostility index and visit required indicator. The dataset included clinics in 31 states total.

We operationalized the primary outcome of interest, adoption of innovative medication abortion practices, through five binary variables: (1) changes to require ultrasound for fewer patients in order to minimize in-person contact before the abortion, (2) adoption of low-or notest abortion (LNTA) protocols (3) offering medication pick-up wherein patients receive the medication in a brief no-exam encounter, (4) mail delivery of abortion medications, and (5) newly offering telehealth visits for medication abortion follow-up (Supplemental Table 2 ).

We performed Fisher's exact tests to assess the relationship between the abortion service delivery innovations and both the state hostility index and visit required indicator. Clinics with missing outcomes were excluded. Due to the small sample size, we made the state hostility index binary (0="Low or Medium"; 1="High or Extreme") to conduct statistical tests. All analyses were conducted in RV3.6.0.

The number of clinics in states classified as having low, medium, high, or extreme restrictions were respectively 34 (60%), 6 (11%), 7 (12%), and 10 (18%). Ten (18%) clinics required in-person visits for medication abortions due to state-level abortion restrictions.

Thirteen (23%; n=2 missing) clinics changed their ultrasound policy, 19 (33%) adopted LNTA protocols, 6 (11%; n=1 missing) allowed curbside medication abortion pick-up, 5 (9%; n=1 missing) offered mail delivery of medication abortion, and 42 (74%) adopted telehealth followup.

Compared to clinics in states with high or extremely high abortion restrictions, clinics in low or medium states were more likely to: change ultrasound requirements (33% vs 0%; p-value=.005), adopt LNTA protocols (40% vs 18%; p-value=.132), provide curbside medication pick-up (13% vs 6%; p-value=.656), provide mail delivery of medication abortion (13% vs 0%, p-value=0.309), and offer telehealth follow-up (85% vs 47%; p-value=.007) ( Figure 1A ).

Compared to clinics in states that require in-person visits for medication abortions, states with no such requirements were more likely to: change ultrasound requirements (28% vs 0%; p-value=.095), adopt LNTA protocols (38% vs 10%; p-value=.140), provide curbside medication pick-up (13% vs 0%; p-value=.578), provide mail delivery of medication abortion (11% vs. 0%, p-value=0.573, and provide telehealth for follow-up (79% vs 50%; p-value=0.108) ( Figure 1B ).

Clinics in more hostile states were less likely to offer patients options to mitigate their risk of acquiring SARS CoV-2 infection in healthcare settings. Further, providers in states that require in-person dispensing of mifepristone were less likely to offer telehealth follow-up despite there being no state-level regulation requiring this care be delivered in person. These results have implications for the impact of the state environment on adoption of public health best practices.

These results should be interpreted in light of several limitations. The small sample size limited our ability to detect differences according to policy environment; thus, we may underestimate the true influence of abortion restrictions on service delivery innovation during the early COVID-19 pandemic. In addition, all outcomes asked about changes during the pandemic.

We did not have data on adoption of these innovative practices previously. While some, such as telemedicine abortion outside of a site-to-site model, were not possible except as part of a research protocol prior to the pandemic [12] , others such as waiving ultrasound requirements may have been adopted before 2020. Lastly, these data are drawn from a convenience sample and may not reflect the true prevalence of service delivery innovations that took place during the COVID-19 pandemic. However, because there was significant variability in state legislative hostility in our sample, the validity of the observed associations between state policy and practice innovation is not threatened by this lack of generalizability.

Evidence for the safety and efficacy of telehealth abortion has increased during the COVID-19 pandemic, leading the FDA to announce that it was reviewing current federal restrictions on mifepristone dispensing [13] [14] [15] . If the in-person dispensing requirement is repealed, this could vastly improve access to medication telehealth [10] . However, the positive impact of such a repeal on abortion access may vary substantially depending on other state-level abortion restrictions. 

Abortion Safety and Use with Normally Prescribed Mifepristone in Canada

Sixteen Years of Overregulation: Time to Unburden Mifeprex

Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond

FDA Announces Long Sought-after Review of Harmful Restrictions on Medication Abortion

State and federal abortion restrictions increase risk of COVID-19 exposure by mandating unnecessary clinic visits

Ibis Reproductive Health [Internet.] Evaluating Priorities. Ibis Reproductive Health and Center for Reproductive rights

Women's Health Indicators: Abortion Statistics and Policies

State Legislation Tracker

State Abortion Policies and Maternal Death in the United States

Variation in Restrictive Abortion Policies and Adverse Birth Outcomes in the United States from 2005 to 2015. Women's Health Issues

Changes to medication abortion clinical practices in response to the COVID-19 pandemic

TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States

Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study

Telemedicine medical abortion at home under 12 weeks' gestation: a prospective observational cohort study during the COVID-19 pandemic

Expansion of a direct-topatient telemedicine abortion service in the United States and experience during the COVID-19 pandemic

Abortion Incidence and Service Availability the United States

The impact of laws requiring parental involvement for abortion: a literature review

Massachusetts' parental consent law and procedural timing among adolescents undergoing abortion

Reasons for and Logistical Burdens of Judicial Bypass for Abortion in Illinois

New evidence on the effects of mandatory waiting periods for abortion

Strong evidence that difficulty paying for abortion is a primary driver of delayed or denied access to abortion care across states and over time

The Medicaid cutoff and abortion services for the poor

Timing of steps and reasons for delays in obtaining abortions in the United States

Delays in request for pregnancy termination: comparison of patients in the first and second trimesters

We would like to thank Mary Tschann, and Elizabeth Ly at the Society for Family Planning for access to the Family planning visits during the COVID-19 pandemic dataset and feedback on our manuscript. We would also like to thank Hannah Lange and Jenny O'Donnell for further clarifications regarding the dataset during the revision process.

Procedural abortion must be provided by a licensed 2 Physician-only laws restrict the number of abortion providers in a state, which in turn limits access to physician abortion. [